or III studies is 20mgm-2 day-' day for 6 weeks.
The standard treatment for stage III non-small-cell lung cancer (NSCLC) is local thoracic irradiation. In 1973 a Radiation Therapy Oncology Group trial showed a significant relationship between higher total dose of radiation and control of tumour within the field as well as survival at 2 years (Perez et al., 1982) . However, the high rate of distant metastases and the still frequent failure within the irradiated volume made the improvement in prognosis rather limited (Perez et al., 1987) . These failures provided a rationale for the combination of radiation and chemotherapy.
For several years induction chemotherapy followed by radiotherapy was used to reduce local and distant recurrences and to improve survival. Some randomised trials showed improved survival with this approach (Dillman et al., 1990; LeChevalier et al., 1992) , however others could not demonstrate the value of induction chemotherapy (Cullen et al., 1991; Mattson et al., 1991; Morton et al., 1991) . A new approach would be simultaneous administration of chemotherapy and radiation therapy. In addition to a cytoreduction by both treatments, a radiosensitising effect might be of extra benefit. In vitro, radiosensitising effects have been found for cisplatin and carboplatin (Douple, 1979; Douple et al., 1985; Begg et al., 1987; Skov and MacPhail, 1991) . Furthermore, platinum-containing regimens in adequate doses have shown objective responses to clinical trials with NSCLC (Bunn, 1989) . In at least one out of four randomised trials concurrent chemoradiation showed improved local control and doubling of the 2 year survival at the cost of considerable toxicity (Soresi et al., 1988; Ansari et al., 1991; Trovo et al., 1991; Schaake-Koning et al., 1992) . Carboplatin has reduced most of the toxicities of cisplatin treatment, especially when it is administered as a continuous infusion (Smit et al., 1991) . In the present study the feasibility and optimal dose of continuous carboplatin infusion on an outpatient basis during local thoracic irradiation in stage III NSCLC was analysed.
Patients and methods

Patients
Patients with histologically proven NSCLC were eligible if they fulfilled the following criteria: age below 75 years, locally unresectable NSCLC without supraclavicular nodes, Eastern Cooperative Oncology Group (ECOG) performance score < 2, serum creatinine < 120 tmol ' or creatinine clearance > 60 ml min-l, serum bilirubin < 2.0 mg dl-' leucocytes > 3.0 x I0 1'-and platelets > 100 x I0 I-1. 
Results
Patients Twenty-one patients were entered into this study. Their characteristics are shown in Table I . Their median age is 60 years (range 35-71) with a male-female ratio of 19:2. One patient suffered a relapse after lobectomy 1 year before. In the other patients no previous malignancies had been diagnosed. Eleven patients gained weight during treatment, seven had a stable weight and three lost weight. Performance score (ECOG) improved in ten patients by 1 point and 11 remained stable. There was one CR (confirmed by surgical resection), ten PRs, six SDs and four PDs.
Toxicity
Nineteen patients completed the treatment. In two patients at the last dose level of 25 mgm2 day-' carboplatin infusion was stopped on days 31 and 28. The first patient developed an infection at the VAP due to Staphyloccus aureus with neutropenic fever. After removal of the VAP leucopenia and temperature normalised within 5 days. In this patient radiotherapy was postponed for 1 week. In the other patient leucocytopenia grade IV and thrombocytopenia grade III led to stopping of carboplatin, but not of irradiation. Another complication of the VAP catheter was thrombosis of the subclavian vein 3 weeks after the end of the treatment (15 mg m2 day' x 31 days). Because of these complications, in the last three patients we used a percutaneously inserted venous catheter in the elbow with tip placement in the superior vena cava (Gesco Per-Q-Cath, San Antonio, Tx, USA). There were no complications.
Haemotological toxicity was dose limiting. Thrombocytopenia developed at the highest dose level in the fifth and sixth weeks of treatment, preceding leucocytopenia, which was prominent 1 week after the end of treatment. Both recovered within 2 weeks after completion of treatment. The nadir of leucocytes and platelets is given in Table II . No haematological toxicity was seen when carboplatin was given Non-haematological toxicity is described in Table III . Oesophagitis was mild and most prominent in the fourth week of treatment. It subsided in the second week after the end of treatment, except in two patients whose complaints disappeared in the third week. With a follow-up of 1 year no late oesophagitis had been encountered. The mean length of the oesophagus in the radiation field up to 40 Gy was 19 cm and thereafter 14 cm with no differences between oesophagitis WHO grades 0, 1 and 2. Acute radiation damage was also mild: dry cough and slight radiographic haziness in the radiation field from the fourth week on led to WHO grade II toxicity in all patients. Clinical features of pneumonitis such as fever did not develop. Corticosteroids were not used. Spinal cord damage and alopecia did not occur.
Lung function
Diffusion capacity corrected for alveolar volume (Kco) measured in 12 patients (the last three dose levels) before treatment was slightly decreased compared with age-and gender-matched controls: 77% (26) of predicted (s.d.). There was no change in Kco during and 2 weeks after treatment.
The pulmonary membrane factor (Dm) and capillary blood volume (V,.p) were also reduced before treatment: 58% (18) of predicted and 75% (32) of predicted respectively. Neither of them changed significantly during or 2 weeks after treatment. The total lung capacity before, during and after treatment was 85% (15), 81% (12) and 87% (7) of predicted (Table IV) .
Pharmacokinetics
From the 15 mg m2 day-' for 6 weeks carboplatin pharmacokinetics on three patients were analysed at each dose level. (Figure 2 ). The residuals showed no evidence of non-randomness.
Discussion
Traditionally, thoracic radiotherapy is the main treatment for local inoperable NSCLC, despite the fact that its role is not well defined (Kjaer, 1982. min-1-') with matched controls, which might be interpreted as a more extensive interstitial or small vessel involvement than could thrombocytopenia and AUC for be expected from CT scan of the chest alone. However, line is theg95o confidence interval during and after the combined treatment neither factors changed. Animal studies with irradiation showed inflammatory cells and protein leak in bronchoalveolar lavage fluid and in histological sections of the lung from 2 weeks after radiation exposure (Travis, 1980; Rosiello, 1993 al., 1986; Tanabe et al., 1987; Steel, 1988) . 'erez et al., 1987 Local tumour control is determined by tumour size, radiation dose, tumour resistance factors, performance score and to a lesser extent the intrapulmonary localisation. Tumour size is important because sterilisation of tumour cells is only possible in small tumours (Dosoretz et al., 1993) . Also chemotherapy achieves better results in smaller tumours. For radiobiological reasons split-course radiation incorporated into combination treatment is inferior to continuous radiation probably owing to repopulation or regeneration with resistant tumour cells during the split period. The effects of irradiation on local tumour control are difficult to assess because of an extensive fibrotic reaction around the shrinking tumour. Response rates of about 50% have been reported (Perez et al., 1982; Dosoretz et al., 1993) . The response rate to carboplatin alone of NSCLC patients is low at around 10% (Kreisman et al., 1987; Bunn, 1992) . In a phase I study with continuous carboplatin infusions alone 5/17 evaluable patients with advanced malignancies responded (Smit et al., 1991) . However, pure local radiation treatment hardly influenced survival (Perez et al., 1982) , while systemic treatment with platinum drugs offers slightly improved survival (Dillman et al., 1990; Schaake-Koning et al., 1992) .
In conclusion, the optimal dose for continuous carboplatin infusion over 6 weeks is 20mgm-2day-' in combination with locoregional fractionated radiation therapy of 30 fractions of 2 Gy. Toxicity has been remarkably mild. A phase III study is necessary to evaluate survival benefit and clinical impact on local control and quality of life for a large group of inoperable stage III NSCLC patients.
